[JUST UPDATED] Global Regenerative Medicine Industry Database, 2026 – Featuring 1,935+ Companies Worldwide

描述

Just updated for August 2026, for a limited time, you can claim this database for 50% off. This offer expires Friday, August 7th, 2026.

Provided instantly as an Excel database, this is the world’s only searchable, sortable database of all known regenerative medicine companies worldwide.

Regenerative medicine (RM) companies are multiplying in number. There are now an astonishing 1,935+ companies developing regenerative medicine products to advance human health.

Updated for August 2026

This August 2026 edition of the Global Regenerative Medicine Industry Database has been refreshed with 52 newly added companies spanning cell therapy, gene therapy, tissue engineering, exosome therapeutics, and beyond, across all major innovation hubs, including the United States, China, Japan, South Korea, Israel, Taiwan, Switzerland, and Poland.

It reflects the latest wave of CAR-T, CAR-NK, in vivo gene editing, iPSC-derived, and organoid-based regenerative platforms to emerge from recent funding rounds, clinical milestones, and market launches. Coverage now extends deeper into stem cell therapies for the treatment of chronic and acute diseases, next-generation CAR-T developers across the US, China, India, Israel, the EU, and Japan, and emerging regenerative medicine hotspots in Japan and Israel.

Companies that have gone out of business have been removed and companies that have merged have been consolidated into a single entry.

This comprehensive global database includes: Name of Company, Company Website, City/State, Country, Phone Number, Email Contact, LinkedIn Page, and a description of each company’s therapeutic platform.

While the rate of growth has slowed somewhat compared to prior years, the addition of 52 new RM companies was being driven by:

• A maturing science base that spins out new companies rather than folding them into existing ones
• Large pharma using licensing and acquisition as its regenerative medicine R&D strategy
• Government-backed regenerative medicine hubs expanding beyond the traditional US/EU centers — China, South Korea, Japan, and Israel are funding dedicated infrastructure and incubators.

Most importantly, this comprehensive global database was created, vetted, and verified by BioInformant’s human analysts, not AI, who have extensive experience tracking rapidly evolving regenerative medicine markets.

Regenerative Medicine (RM) Industry Database

Because the number of companies can vary depending on the definition of regenerative medicine that is applied, we define regenerative medicine companies as those pursuing therapeutic approaches that include stem cell therapies, cellular immunotherapies, gene therapies, tissue engineering and biomaterials, direct cell reprogramming, exosome therapeutics, cellular scaffolds and matrices, and 3D bioprinting.

We believe this definition of regenerative medicine provides the most accurate coverage of the regenerative medicine (RM) industry and its annual rate of growth.

Global Database of Regenerative Medicine Companies

As you can imagine, takes our team of experienced analysts a vast amount of research to uncover newly launched companies from across the globe. We utilize numerous translators to discover companies doing business across a wide range of languages.

We crowd-source feedback from BioInformant’s partners, clients, and readership who contribute new additions and submit company profiles. We are also frequently notified when companies emerge from “stealth mode”. 

Simply put, the quality of this database would not be possible without the past 19+ years of following this industry and developing proprietary datasets (to which AI does not have access).

These insights exist because they are built on nearly two decades of granular tracking, industry interviews, and daily monitoring of the regenerative medicine  landscape. It is only possible because of our deep relationships within the industry.

To ensure its completeness, we also examine the following sources:

• ClinicalTrials.gov, a Global Clinical Trial Database
• U.S. Patent and Trademark Office (USPTO)
• World Intellectual Property Organization (WIPO)
• PubMed.gov, a Biomedical Literature Database
• Funding Announcements
• Conference Registration Lists
• BioInformant’s Client & Partners

The end result is the world’s only searchable, sortable database of regenerative medicine companies that is publicly available.

If you want immediate and actionable insights from a trusted, U.S. based provider that specializes exclusively in cell therapy market insights, then this database is for you. Because it is an essential resource within our company, we are confident it will be an invaluable resource to you too.

Clients commonly use it to identify: